Valuation: Lord Global Corporation

Market Cap 5.28M 4.62M 4.34M 3.96M 7.43M 505M 7.43M 52.06M 20.09M 258M 19.83M 19.4M 831M P/E 2018 *
-
P/E 2019 -0.6x
Enterprise Value 5.89M 5.15M 4.84M 4.41M 8.28M 563M 8.29M 58.06M 22.4M 288M 22.12M 21.63M 927M EV / Sales 2018
1,290x
EV / Sales 2019 1,135x
Free-Float
25.63%
Yield 2018 *
-
Yield 2019 -
1 day+100.00%
1 week-33.33%
1 month 0
Extreme 0.0002
0
Current year 0
Extreme 0.0002
0
1 year 0
Extreme 0.0002
0
3 years 0
Extreme 0.0002
0
5 years 0
Extreme 0.0001
0.6
10 years 0
Extreme 0
75,000
Manager TitleAgeSince
Chief Executive Officer 36 23/01/2020
Director TitleAgeSince
Chairman 36 23/01/2020
Change 5-day change 1-year change 3-year change Capi.($)
+100.00%-33.33%-.--%+100.00% 559
+2.02%-8.17%-45.67%-20.02% 11.34B
-0.87%+0.85%+84.07%+119.56% 9.55B
-2.17%-2.35%-14.08%+49.47% 8.35B
+1.58%+15.48%-39.98%-29.46% 5.39B
+0.09%+3.31%-39.95%+30.89% 4.92B
+1.44%+0.71%-5.25%-5.25% 4.15B
+0.15%+8.05%-19.73%-5.18% 3.78B
-1.05%+1.52%+65.60%+50.21% 3.38B
+1.89%+8.01%-19.85%+28.84% 2.11B
Average +10.31%+2.38%-3.48%+31.91% 5.3B
Weighted average by Cap. +0.23%+0.70%-3.05%+28.51%

Financials

2018 2019
Net sales 2.83K 2.47K 2.32K 2.12K 3.98K 270K 3.98K 27.87K 10.75K 138K 10.62K 10.38K 445K 888 776.02 729.36 665.58 1.25K 84.89K 1.25K 8.75K 3.38K 43.35K 3.33K 3.26K 140K
Net income -6.43M -5.62M -5.28M -4.82M -9.05M -615M -9.05M -63.42M -24.47M -314M -24.16M -23.63M -1.01B -491K -429K -403K -368K -690K -46.91M -690K -4.84M -1.87M -23.96M -1.84M -1.8M -77.23M
Net Debt 651K 568K 534K 488K 915K 62.19M 915K 6.41M 2.47M 31.76M 2.44M 2.39M 102M 608K 531K 499K 455K 855K 58.09M 855K 5.99M 2.31M 29.67M 2.28M 2.23M 95.64M
Logo Lord Global Corporation
27 Health Holdings Corp., formerly Lord Global Corporation, is focused on the business development of its 27Health Inc. subsidiary. 27Health Inc. is focused on financing and marketing, healthcare-related products. The Company distributes the Virolens product in Asia, Australia, New Zealand and other Oceania countries. The Virolens system is a COVID-19 screening device based on microscopic holographic imaging and artificial intelligence (AI) software technology. It uses a digital camera attached to a microscope to analyze saliva samples, with the data run through a computer that is trained to identify the virus from other cells, delivering a result in just 20 seconds. The Virolens system was trained to recognize the COVID-19 virus particles in saliva using a range of samples of COVID-19 virus provided by virologists working on the virus at the University of Bristol.
Employees
-
Date Price Change Volume
  1. Stock Market
  2. Stocks
  3. LRDG Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!